Dimethylamine

Dimethylamine

SCHEMBL2103953

CNC.Cc1cc2cc(N)ccc2o1

nearest known ligand 0.54

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 1/20 0.54
FLT3 P36888 1/20 0.50
CA2 P00918 1/20 0.47
NPC1 O15118 7/20 0.42
MAOB P27338 2/20 0.41
RAB9A P51151 7/20 0.39
MAPT P10636 6/20 0.39
SMN1; SMN2 Q16637 6/20 0.39
KDM4E B2RXH2 6/20 0.39
ALDH1A1 P00352 4/20 0.39
HSD17B10 Q99714 3/20 0.39
TP53 P04637 2/20 0.39
NFKB1 P19838 1/20 0.39
NFKB2 Q00653 1/20 0.39
RELA Q04206 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
APP P05067 2/20 0.38
CHRM2 P08172 1/20 0.38
CHRM4 P08173 1/20 0.38
CHRM5 P08912 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2790760 0.94 DYRK1A (0.59) DYRK1AFLT3CA2NPC1MAOB
Hydrochloric Acid SCHEMBL2482195 0.92 DYRK1A (0.58) DYRK1AFLT3CA2NPC1MAOB
Oxalic Acid SCHEMBL6591344 0.84 FLT3 (0.59) DYRK1AFLT3CA2NPC1MAOB
SCHEMBL6980491 0.78 CA2 (0.52) DYRK1AFLT3CA2NPC1RAB9A
SCHEMBL8311387 0.74 DYRK1A (0.47) DYRK1AMAOBKDM4EALDH1A1APP
SCHEMBL22312245 0.74 DYRK1A (0.51) DYRK1ANPC1MAOBRAB9AKDM4E
SCHEMBL3920685 0.73 FLT3 (0.59) FLT3CA2NPC1MAOBRAB9A
SCHEMBL170369 0.73 ALDH1A1 (0.55) DYRK1ACA2MAOBALDH1A1APP
SCHEMBL16284310 0.72 NPC1 (0.57) FLT3CA2NPC1MAOBRAB9A
SCHEMBL13724073 0.72 FLT3 (0.67) FLT3CA2NPC1RAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2316459-B1 2,4-pyrimidinediamine compounds for use in methods of treating or preventing autoimmune diseases RIGEL PHARMACEUTICALS INC (US) 2013-11-06 EP disclosed
US-8557806-B2 Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds RIGEL PHARMACEUTICALS, INC. (US) 2013-10-15 US disclosed
US-8158621-B2 Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds RIGEL PHARMACEUTICALS, INC. (US) 2012-04-17 US disclosed
US-7825116-B2 -(2-Aminopyrid-6-yl)-5-fluoro-N2-[3-(N-methylamino)carbonylmethyleneoxyphenyl]-2,4-pyrimidinediamine; signal transduction cascade inhibitor; Fc receptors for immunoglobulins IgE and IgG antagonist; autoimmune diseases, antiinflammatory agent; rheumatoid arthritis, multiple sclerosis RIGEL PHARMACEUTICALS, INC. (US) 2010-11-02 US disclosed
US-7812029-B1 such as N4-[(2,2-Dimethyl-4H-benzo[1,4]oxazin-3-one)-6-yl]-5-fluoro-N2-[3-(methylaminocarbonylmethyleneoxy)phenyl]-2,4-pyrimidinediamine; Glomerulonephritis; rheumatoid arthritis; systemic lupus erythematosis; multiple sclerosis RIGEL PHARMACEUTICALS, INC. (US) 2010-10-12 US disclosed
US-7517886-B2 Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds RIGEL PHARMACEUTICALS, INC. (US) 2009-04-14 US disclosed